Cytosine arabinoside in acute granulocytic leukemia

作者：Brian W. Goodell, Brigid G. Leventhal, Edward S. Henderson · 发表于：Clinical Pharmacology & Therapeutics · 年份：1971 · DOI：10.1002/cpt1971124599 · 被引用次数：55 · 研究领域：Acute Lymphoblastic Leukemia research、Acute Myeloid Leukemia Research、Cancer therapeutics and mechanisms

Gytosine arabinoside (Ara‐G) is an antimetabolite of demonstrated activity in acute granulocytic leukemia (AGL). Between 1966 and 1969, 49 patients with AGL received remission induction chemotherapy with this drug at the National Gancer Institute. Ara‐G was given by 4 hour infusion at a dose of 70 to 150 mg. per square meter per day in repeated 4 day courses. Gomplete remissions were achieved in 42 per cent of patients. Of patients receiving Ara‐G as initial chemotherapy, 25 per cent died during attempted induction and 25 per cent attained complete remission; of patients who had received prior chemotherapy (irrespective of response), 67 per cent achieved complete remission (p<0.02). Infection (73 per cent} and hepatic dysfunction (44 per cent) were common complications of therapy. Median duration of remission in 21 patients receiving weekly Ara‐G at 75 mg. per square meter subcutaneously as maintenance chemotherapy was 5 months. Median survival in patients achieving remission with Ara‐G was 17 months; patients failing induction with this drug lived a median of 6 months. Ara‐G is an effective and well‐tolerated chemotherapeutic agent in AGL.